Publications by authors named "R Herriot"
Background: Acquired angioedema due to C1-inhibitor deficiency (AAE-C1-INH) is very rare compared to its prototype, hereditary angioedema. An updated characterisation of the AAE-C1-INH cohort in UK is required to inform management.
Objectives: To describe the disease burden of AAE-C1-INH, long-term prophylaxis (LTP) and the clinical, immunochemical and treatment profiles of AAE-associated diseases in UK.
Background: Within North America and worldwide, drug related overdoses have increased dramatically over the past decade. COVID-19 escalated the need for a safer supply to replace unregulated substances and to reduce toxicity and overdoses. Service providers play an integral role in the delivery of safer supply but there is little empirical evidence that conceptualizes effective safer supply from their perspectives.
View Article and Find Full Text PDFArticle Synopsis
- - The survey aimed to gather comprehensive demographic data on hereditary angioedema (HAE) and acquired C1 inhibitor deficiency in the UK to enhance service planning and patient care.
- - A total of 1152 patients with HAE were identified, with a prevalence of 1:59,000 for HAE-1/2 and 1:734,000 for acquired C1 inhibitor deficiency, revealing significant patient demographics and treatment patterns.
- - Findings showed that 45% of HAE patients were on long-term prophylaxis, primarily using danazol, and a significant number had acute treatment supplies available at home, highlighting the need for improved healthcare services for these conditions.
Article Synopsis
- In March 2020, the UK Primary Immunodeficiency Network created a registry to track outcomes of individuals with Primary Immunodeficiency Diseases (PID) and Secondary Immunodeficiency Diseases (SID) after infection with SARS-CoV-2, reporting 310 cases.
- The overall mortality rate was 17.7%, with certain groups experiencing higher rates; for example, Common Variable Immunodeficiency Disease (CVID) had an infection fatality rate (IFR) of 18.3%.
- Individuals with PID and SID faced greater risks in terms of inpatient mortality and generally died at younger ages than the broader population, with risk factors including older age, low lymphocyte count before infection, and existing co-morbidities